Biosimilars in Oncology

Current Landscape and Future Possibilities in the U.S. and Europe

Rachel Sliman
Senior Director, Data

The availability of of biologic therapies to treat oncology disease conditions has led to improved clinical outcomes, but the high cost can create barriers and disparities in treatment access and outcomes. The use of biosimilars can improve patients’ access to care by decreasing treatment costs and creating price competition between the originator product and biosimilar competitors.

Watch our webinar to learn more about biosimilar approvals and market access.